ema semaglutide naion june 2025 A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no Meeting highlights from the Pharmacovigilance

Early studies and real-world usage suggest that Tirzepatide may yield greater weight reduction in certain patients, especially when compounded and administered under medical supervision

The expression of GLP-1 receptors in eosinophils in asthma patients was significantly lower than in healthy peoples eosinophils, while the number of GLP-1 receptors in neutrophils was the same in both populations

Regarding belly fat specifically, patients should understand that spot reduction is not physiologically possible

In Section Effects of polymorphisms in glucoronosyl transferases we showed that polymorphisms in the glucoronosyl transferase enzymes can have a large effect on the amount of liver damage caused by moderate overdoses of APAP

To complement your treatment, focus on a balanced diet rich in lean proteins, vegetables, and whole grains

[DOI] [PubMed] [Google Scholar] 42.Soto C, Prez J, Garca V, Ura E, Vadillo M, Raya L